STUDY SPONSORSHIP TRANSFERRED - Zevalin post-marketing surveillance in Japan (ZEVALIN-DUI)
DISCLAIMER: This study was originally conducted and disclosed under Bayer sponsorship; sponsorship was however transferred to a new sponsor while the study was still ongoing. Therefore, this disclosure overview only reflects the study status at the last time that Bayer was responsible for the study – for the latest correct status and details of the study, please refer to the disclosure by the new sponsor under the study’s NCT number on www.ClinicalTrials.gov.
This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin’s lymphoma and Mantle cell lymphoma. The objective of this study is to assess safety and efficacy of using Zevalin in clinical practice. This study is also all case investigation of which the enrollment period is five years, and all patients who received Zevalin will be recruited and followed 13 weeks after the administration.
Patients who received Zevalin for relapsed or refractory: - CD20+ - low grade B-cell non-Hodgkin’s lymphoma - Mantle cell lymphoma
- Patients who are contraindicated based on the product label
Many Locations, Japan
E-mail: [email protected]
Phone: Not Available
Drug use investigation of Zevalin